| Literature DB >> 31915453 |
Zaid O Ibraheem1,2, Roslaini Abd Majid3, Hasidah Mohd Sidek4, Sabariah Md Noor5, Mun Fei Yam6, Mohammad Faruq Abd Rachman Isnadi2, Rusliza Basir2.
Abstract
The emergence of drug-resistant strains of Plasmodium falciparum is the worst catastrophe that has ever confronted the dedicated efforts to eradicate malaria. This urged for searching other alternatives or sensitizers that reverse chloroquine resistance. In this experiment, the potential of andrographolide to inhibit plasmodial growth and reverse CQ resistance was tested in vitro using the SYBRE green-1-based drug sensitivity assay and isobologram technique, respectively. Its safety level toward mammalian cells was screened as well against Vero cells and RBCs using MTT-based drug sensitivity and RBC hemolysis assays, respectively. Its effect against hemozoin formation was screened using β-hematin formation and heme fractionation assays. Its molecular characters were determined using the conventional tests for the antioxidant effect measurement and the in silico molecular characterization using the online free chemi-informatic Molinspiration software. Results showed that andrographolide has a moderate antiplasmodium effect that does not entitle it to be a substituent for chloroquine. Furthermore, andrographolide ameliorated the sensitivity of the parasite to chloroquine. Besides, it showed an indirect inhibitory effect against hemozoin formation within the parasite and augmented the chloroquine-induced inhibition of hemozoin formation. The study suggests that its chloroquine resistance reversal effect may be due to inhibition of chloroquine accumulation or due to its impact on the biological activity of the parasite. Overall, this in vitro study is a clue for the reliability of andrographolide to be added with chloroquine for reversal of chloroquine resistance and tolerance, but further in vivo studies are recommended to confirm this notion. In spite of its prominent and safe in vitro and in vivo growth inhibitory effect and its in vitro chloroquine resistance reversing effect, it is inapplicable to implement it in malaria chemotherapy to substitute chloroquine or to reverse its resistance.Entities:
Year: 2019 PMID: 31915453 PMCID: PMC6930765 DOI: 10.1155/2019/7967980
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
Antioxidant effect of andrographolide using DPPH, hydrogen peroxide scavenging activity, or reducing power assay.
| Antioxidant effect as compared with butylated hydroxytoluene | ||
|---|---|---|
| Andrographolide | BHT | |
| IC50 hydrogen peroxide scavenging activity ( | 112 | 32 |
| Reducing power assay ( | 46 | 2 |
| DPPH assay ( | 88 | 11 |
In silico molecular characters of andrographolide.
|
| |
| C log | 1.287 |
|
| 0 |
| MWt | 350.46 |
| nNO | 5 |
| PSA | 87 |
| nOHNH | 3 |
|
| |
|
| |
| GPCR ligand | 0.2 |
| Ion channel modulator | −0.08 |
| Kinase inhibitor | −0.36 |
| Nuclear receptor ligand | 0.2 |
| Protease inhibitor | 0.13 |
| Enzyme inhibitor | 0.43 |
Cytotoxicity of andrographolide and chloroquine against Plasmodium falciparum, RBCs, and Vero cells and potency classification of compounds against Plasmodium falciparum.
| Drug IC50 range | Extent of potency |
|---|---|
| <1 | Excellent potency |
| 1 | Good activity |
| 20 | Moderate activity |
| 100–200 | Low activity |
| >200 | Inactive |
Cytotoxicity of andrographolide and chloroquine against Plasmodium falciparum, RBCs, and Vero cells and the cytotoxic effect of andrographolide against Plasmodium falciparum (3D7 and K1), Vero cells, and RBCs.
| Andrographolide | Chloroquine | |
|---|---|---|
|
| ||
| g.m.w (g/mole) | 350.5 | 515 |
| Molar concentration ( | 8.56 | 5.83 |
|
| ||
|
| ||
| IC50 against RBCs in | >1000 | >1000 |
| IC50 against Vero cells in | >1000 | >1000 |
|
| 1.4 ± 0.03 | 0.021 ± 0.002 |
| SI compared with RBCs | 992 | >1000 |
| SI compared with Vero cells | 680 | >1000 |
|
| 1.2 ± 0.15 | 0.265 ± 0.05 |
| SI compared with RBCs | 965 | >1000 |
| SI compared with Vero cells | 650 | >1000 |
|
| ||
|
| ||
|
| 23.639 ± 2.76 | 0.043 ± 0.001 |
| SI compared with RBCs | ||
| SI compared with Vero cells | ||
|
| 28.023 ± 6.93 | 0.92 ± 0.05 |
| SI compared with RBCs | 280 | |
| SI compared with Vero cells | ||
The table provided in part A represents the g.m.w of each item and the concentration limit in μM that is equivalent to 30 μg/ml; in part B, IC50 values against the mentioned cells as well as the IC50-based selectivity indices; And in subpart C, IC90 values against the mentioned cells as well as the IC90-based selectivity indices are listed.
Figure 1Antiplasmodium effect of each of andrographolide (a) and chloroquine (b) against Plasmodium falciparum 3D7 and K1. The chloroquine susceptible and resistant strains of Plasmodium falciparum. (a) also shows the dose-response curve for the cytotoxic effect of andrographolide against each of RBCs and Vero cells. Such effects for chloroquine were absent.
Figure 2FIC50- and FIC90-based isobolograms for different combination mixtures of andrographolide and chloroquine at (10 : 0, 7 : 3, 5 : 5, 3 : 7, and 0 : 10 (chloroquine/andrographolide)). The red lines in the two graphs represent lines of additivity. Synergy is considered for the points located above the line of additivity while antagonism is considered for points located above that line.
Results of the FIC50- and FIC90-based isobolograms for CQ/andrographolide mixtures.
| Mixing ratio (CQ/andro) | FIC50-based isobologram | FIC90-based siobologram | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| IC50 CQ in nM | IC50 andro in | FIC50 CQ | FIC50 andro | Total | IC90 CQ in nM | IC90 andro in | FIC90 CQ | FIC90 andro | Total | |
| 10/0 | 269.2 ± 0.4 | 0 | 1.00 | 0.00 | 1.00 | 791.51 ± 0.00 | 0 | 1.00 | 0.000 | 1.00 |
| 7/3 | 184.0 ± 5.4 | 0.32 ± 0.02 | 0.68 | 0.30 | 0.99 | 595.58 ± 42.48 | 1.31 ± 0.068 | 0.75 | 0.06 | 0.81 |
| 5/5 | 128.2 ± 9.7 | 0.51 ± 0.05 | 0.48 | 0.49 | 0.97 | 447.20 ± 36.41 | 2.62 ± 0.13 | 0.56 | 0.10 | 0.66 |
| 3/7 | 95.1 ± 9.2 | 0.91 ± 0.03 | 0.35 | 0.85 | 1.21 | 329.83 ± 39.90 | 4.7 ± 0.35 | 0.42 | 0.17 | 0.59 |
| 0/10 | 0.0 ± 0.00 | 1.08 ± 0.00 | 0.00 | 1.00 | 1.00 | 0.00 ± 0.00 | 26.4 ± 0.91 | 0.00 | 1.00 | 1.00 |
Figure 3Amount of iron Hb, heme, and hemozoin iron produced in cultures Plasmodium falciparum K1 at different parasitemia in the control and untreated flasks (a) as well as in flasks treated with IC50 and IC90 concentration of each of chloroquine (b) and andrographolide (c). (d–f) show the amount of iron fractions (Hb, heme, or Hz) produced by the parasite after exposure to combinations of chloroquine and andrographolide at different combination levels (7 : 3, 5 : 5, and 3 : 7 (chloroquine/andrographolide)). The amount of iron in each fraction was estimated in fg of iron/cell. The results are expressed as log (amount of iron in each fraction in fg) in ordinate versus the parasitemia level in abscissa. X axis of the treated flask shows the parasitemia level after 24 h of exposure to the determined dose and the concentration of the drug (IC50 or IC90). For the combinations, both chloroquine and andrographolide were combined at their IC50 and IC90 at different ratios (7 : 3, 5 : 5, and 3 : 7 (chloroquine/andrographolide)). , , and signify statistically significant change as compared with that of the same parasitemia level of the positive control. While $, $$, and $$$ signify a statistically significant difference as compared with the cohort flask of andrographolide-treated flasks.